Clinical radionuclide therapy

Targeted Radionuclide Tumor Therapy: Biological Aspects

Volumn , Issue , 2008, Pages 349-385

  Scott, Andrew M ^a,b,c   Lee, Sze Ting ^a,b,c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892073152     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8696-0_20     Document Type: Chapter

References (230)

1. Abrahamsson PA (1999) Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 6:503-19
2. Ahlman H (2006) Malignant pheochromocytoma: state of the field with future projections. Ann N Y Acad Sci 1073:449-64
3. Ain KB, Taylor KD, Tofiq S, Venkataraman G (1997) Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857-62
4. Alexander RW, Upp JR, Jr., Poston GJ, Gupta V, Townsend CM, Jr., Thompson JC (1988) Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res 48:1439-41
5. Ali N, Sebastian C, Foley RR, Murray I, Canizales AL, Jenkins PJ, Drake WM, Plowman PN, Besser GM, Chew SL, Grossman AB, Monson JP, Britton KE (2006) The management of differentiated thyroid cancer using 123I for imaging to assess the need for 131I therapy. Nucl Med Commun 27:165-9
6. Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J (2005) Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 4:1318-24
7. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O (1998) Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 383:160-3
8. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, Russell CD, Liu T, Grizzle WE, Schlom J, Lo Buglio AF, Meredith RF (1997) Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65:94-101
9. Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, Lo Buglio AF (2002) A phase I study of combined modality (90) Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8:2806-11
10. Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ, McCarthy KE (2002) Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 32:123-32
11. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23:4591-601
12. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G (2003) Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-5
13. Bartholdi MF, Wu JM, Pu H, Troncoso P, Eden PA, Feldman RI (1998) In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma. Int J Cancer 79:82-90
14. Baselga J (2001) Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials. Oncology 61 Suppl 2:14-21
15. Behr TM, Gotthardt M, Barth A, Behe M (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189-200
16. Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F, Becker W (1999) Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40:1029-44
17. Behr TM, Jenner N, Radetzky S, Behe M, Gratz S, Yucekent S, Raue F, Becker W (1998) Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25:424-30
18. Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, Gratz S, Angerstein C, Brittinger G, Becker H, Goldenberg DM, Becker W (2002) Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94:1373-81
19. Beierwaltes WH (1978) The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79-94
20. Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, Divgi C, Zanzonico P, Stare J, Buscombe J, Minh CT, Saw MM, Chen S, Ogbac R, Padhy AK (2007) Intra-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: results of an IAEA-sponsored multination study. Int J Radiat Oncol Biol Phys 69:1448-55
21. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, Macke H, de Jong M (1997) D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 38:1929-33
22. Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R (2005) Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin Cancer Res 11:7070s-4s
23. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31:1038-46
24. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 30:207-16
25. Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, Lopera Sierra M, Cremonesi M, Chinol M, Macke HR, Paganelli G (2004) Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 19:65-71
26. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44:400-11
27. Bold RJ, Ishizuka J, Yao CZ, Townsend CM, Jr., Thompson JC (1998) Bombesin stimulates in vitro growth of human breast cancer independent of estrogen receptors status. Anticancer Res 18:4051-6
28. Bomanji J, Britton KE, Ur E, Hawkins L, Grossman AB, Besser GM (1993) Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine. Nucl Med Commun 14:856-61
29. Boxer GM, Begent RH, Kelly AM, Southall PJ, Blair SB, Theodorou NA, Dawson PM, Ledermann JA (1992) Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma-implications for radioimmunotherapy. Br J Cancer 65:825-31
30. Brans B, De Winter F, Defreyne L, Troisi R, Vanlangenhove P, Van Vlierberghe H, Lambert B, Praet M, de Hemptinne B, Dierckx RA (2001) The anti-tumoral activity of neoadjuvant intra-arterial 131I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 16:333-8
31. Brans B, Van Laere K, Gemmel F, Defreyne L, Vanlangenhove P, Troisi R, Van Vlierberghe H, Colle I, De Hemptinne B, Dierckx RA (2002) Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 29:928-32
32. Brouwers AH, Dorr U, Lang O, Boerman OC, Oyen WJ, Steffens MG, Oosterwijk E, Mergenthaler HG, Bihl H, Corstens FH (2002) 131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl Med Commun 23:229-36
33. Buhl T, Mortensen J, Kjaer A (2002) I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: a case report. Clin Nucl Med 27:183-5
34. Burke PA, De Nardo SJ, Miers LA, Kukis DL, De Nardo GL (2002) Combined modality radioimmunotherapy: promise and peril. Cancer 94:1320-31
35. Carney DN, Cuttitta F, Moody TW, Minna JD (1987) Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 47:821-5
36. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV (1999) Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 276:G655-65
37. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24:1705-11
38. Chen S, Yu L, Jiang C, Zhao Y, Sun D, Li S, Liao G, Chen Y, Fu Q, Tao Q, Ye D, Hu P, Khawli LA, Taylor CR, Epstein AL, Ju DW (2005) Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. J Clin Oncol 23:1538-47
39. Cheson BD (2006) Radioimmunotherapy of non-Hodgkin's lymphomas. Curr Drug Targets 7:1293-300
40. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, U P, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O'Keefe G J, Burgess AW, Hoffman EW, Old LJ, Scott AM (2005) Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res 11:4818-26
41. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14:569-85
42. Christiansen J, Rajasekaran AK (2004) Biological impediments to monoclonal antibodybased cancer immunotherapy. Mol Cancer Ther 3:1493-501
43. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM (2000) Therapeutic efficacy of anti-Lewis (y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 6:3621-8
44. Coakley AJ (1998) Thyroid stunning. Eur J Nucl Med 25:203-4
45. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9:797-804
46. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-42
47. Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823-6
48. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ (2004) The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10:7792-8
49. de Baere T, Taourel P, Tubiana JM, Kuoch V, Ducreux M, Lumbroso J, Roche AJ (1999) Hepatic intraarterial 131I iodized oil for treatment of hepatocellular carcinoma in patients with impeded portal venous flow. Radiology 212:665-8
50. de Jong M, Krenning E (2002) New advances in peptide receptor radionuclide therapy. J Nucl Med 43:617-20
51. de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, van Gameren A, Krenning EP (2001) Tumor response after [(90) Y-DOTA (0), Tyr (3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 42:1841-6
52. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 32:133-40
53. De Kraker J, Hoefnagel CA, Caron H, Valdes Olmos RA, Zsiros J, Heij HA, Voute PA (1995) First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer 31 A: 600-2
54. De Nardo GL, Siantar CL, De Nardo SJ (2002) Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy. Cancer Biother Radiopharm 17:107-18
55. De Nardo GL, Tobin E, Chan K, Bradt BM, De Nardo SJ (2005) Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res 11:7075s-9s
56. De Nardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell RT, Kukis DL, Richman CM, De Nardo GL (1997) Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma. Cancer 80:2583-90
57. Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ (2004) Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 45:1412-21
58. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Ginter CS, Carrasco N (2003) The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24:48-77
59. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L (1995) Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36:21-7
60. Dow KH, Ferrell BR, Anello C (1997) Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7:613-9
61. Du Bois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK (2004) Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 22:2452-60
62. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young WF, Jr. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423-36
63. Ferris HA, Carroll RE, Lorimer DL, Benya RV (1997) Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells. Peptides 18:663-72
64. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK (2006) Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 1073:465-90
65. Flynn AA, Boxer GM, Begent RH, Pedley RB (2001) Relationship between tumour morphology, antigen and antibody distribution measured by fusion of digital phosphor and photographic images. Cancer Immunol Immunother 50:77-81
66. Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, Lo Buglio AF, Robert F (2005) Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 20:467-78
67. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, Eisenwiener K, Beglinger C, Macke HR (2002) Neuroendocrine tumor targeting: study of novel galliumlabeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 98:930-7
68. Goetz C, Riva P, Poepperl G, Gildehaus FJ, Hischa A, Tatsch K, Reulen HJ (2003) Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol 62:321-8
69. Goldberg SS, De Santes K, Huberty JP, Price D, Hasegawa BH, Reynolds CP, Seeger RC, Hattner R, Matthay KK (1998) Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma. Med Pediatr Oncol 30:339-46
70. Goldenberg DM, Sharkey RM (2007) Novel radiolabeled antibody conjugates. Oncogene 26:3734-44
71. Goldstein D, Van Hazel G, Pavlakis N, Olver I (2005) Selective internal radiation therapy (SIRT) plus systemic chemotherapy with irinotecan. A phase I dose escalation study. J Clin Oncol 23: (Abstract 3701)
72. Gotthardt M, Dijkgraaf I, Boerman OC, Oyen WJ (2006) Nuclear medicine imaging and therapy of neuroendocrine tumours. Cancer Imaging 6:S178-84
73. Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJ (2004) Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 10:2951-63
74. Gotthardt M, Battmann A, Beuter D, Bauhofer A, Schipper M, Behe M, et al. (2003) Comparison of In-111-D-Glu-1-Mingastrin, F-18-FDG PET, and CT scanning for detection of metastatic medullary thyroid carcinoma. J Nucl Med 44:169P
75. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V (2001) Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:1711-20
76. 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7:327-35
77. Gugger M, Reubi JC (1999) Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155:2067-76
78. Hajjar G, Sharkey RM, Burton J, Zhang CH, Yeldell D, Matthies A, Alavi A, Losman MJ, Brenner A, Goldenberg DM (2002) Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2:31-42
79. Hajri A, Koenig M, Balboni G, Damge C (1996) Expression and characterization of gastrinreleasing peptide receptor in normal and cancerous pancreas. Pancreas 12:25-35
80. Hall P, Boice JD, Jr., Berg G, Bjelkengren G, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, et al. (1992) Leukaemia incidence after iodine-131 exposure. Lancet 340:1-4
81. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-54
82. Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V (2004) Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272-80
83. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, De Groot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-85
84. Heppeler A, Froidevaux S, Eberle AN, Maecke HR (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7:971-94
85. Herbertson R, Tebbutt N, Gill S, Lee FT, Chapell B, Cavicchiolo T, Skrinos E, Poon A, Saunder T, Scott AM (2007) Targeted chemoradiation for metastatic colorectal cancer: a phase I trial of oral capecitabine combined with 131I-huA33. J Clin Oncol 2007. ASCO Annual Meeting Proceedings 25:183s (Abstract 4078)
86. Hernandez MC, Knox SJ (2004) Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 59:1274-87
87. Hessenius C, Bader M, Meinhold H, Bohmig M, Faiss S, Reubi JC, Wiedenmann B (2000) Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours. Eur J Nucl Med 27:1684-93
88. Ho S, Lau W Y, Leung TW, Johnson PJ (1998) Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Cancer 83:1894-907
89. Hoefnagel CA, Voute PA, de Kraker J, Marcuse HR (1987) Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 28:308-14
90. Hoefnagel CA, De Kraker J, Valdes Olmos RA, Voute PA (1994) 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun 15:712-7
91. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50:814s-9s
92. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, de Camps J, Schran H, Chen T, Smith MC, Bouterfa H, Valkema R, Krenning EP, Kvols LK, Pauwels S (2003) 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30:510-8
93. Jensen JA, Carroll RE, Benya RV (2001) The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22:689-99
94. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV (1997) Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 32:164-72
95. Jungwirth A, Pinski J, Galvan G, Halmos G, Szepeshazi K, Cai RZ, Groot K, Vadillo-Buenfil M, Schally AV (1997) Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 33:1141-8
96. Jurcic JG, Caron PC, Scheinberg DA (1995) Monoclonal antibody therapy of leukemia and lymphoma. Adv Pharmacol 33:287-314
97. Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, Miller WH, Jr., Geerlings MW, Warrell RP, Jr., Larson SM, et al. (1995) Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res 55:5908s-10s
98. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA (2002) Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100:1233-9
99. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM, et al. (1993) Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-65
100. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-9
101. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974-81
102. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-66
103. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-28
104. Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM (2007) Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy. Clin Cancer Res 13:5604s-12s
105. Koerber C, Schmutzler C, Rendl J, Koehrle J, Griesser H, Simon D, Reiners C (1999) Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid. Clin Nucl Med 24:849-51
106. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins J (1999) Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:912-6
107. Kotzerke J, Bunjes D, Scheinberg DA (2005) Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplant 36:1021-6
108. Kraeber-Bodere F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardies M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J (2003) Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9:3973S-81S
109. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al. (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-31
110. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP (2001) [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 28:1319-25
111. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23:2754-62
112. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL, Krenning EP (2003) Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA (0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging 30:417-22
113. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, O'Dorisio T M, Valkema R, Bodei L, Chinol M, Maecke HR, Krenning EP (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46 Suppl 1:62S-6S
114. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, De Groot LJ, Daniels GH, Ross DS, Weintraub BD (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-96
115. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ (1996) Octreotide. N Engl J Med 334:246-54
116. Lantry LE, Cappelletti E, Maddalena ME, Fox JS, Feng W, Chen J, Thomas R, Eaton SM, Bogdan NJ, Arunachalam T, Reubi JC, Raju N, Metcalfe EC, Lattuada L, Linder KE, Swenson RE, Tweedle MF, Nunn AD (2006) 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47:1144-52
117. Lashford LS, Lewis IJ, Fielding SL, Flower MA, Meller S, Kemshead JT, Ackery D (1992) Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 10:1889-96
118. Lau WY, Leung TW, Ho SK, Chan M, Machin D, Lau J, Chan AT, Yeo W, Mok TS, Yu SC, Leung NW, Johnson PJ (1999) Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797-801
119. Leahy MF, Seymour JF, Hicks RJ, Turner JH (2006) Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 24:4418-25
120. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J (1998) Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 25:242-6
121. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ (2005) Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696-704
122. Liebmann J, Cook JA, Teague D, Fisher J, Mitchell JB (1994) Cycloheximide inhibits the cytotoxicity of paclitaxel (Taxol). Anticancer Drugs 5:287-92
123. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM (2005) Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 23:6763-70
124. Lind P, Kohlfurst S (2006) Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med 36:194-205
125. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20:648-58
126. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F (2005) rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49-64
127. Maecke HR, Hofmann M, Haberkorn U (2005) (68) Ga-labeled peptides in tumor imaging. J Nucl Med 46 Suppl 1:172S-8S
128. Mahe MA, Fumoleau P, Fabbro M, Guastalla JP, Faurous P, Chauvot P, Chetanoud L, Classe JM, Rouanet P, Chatal JF (1999) A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5:3249s-53s
129. Mandel SJ, Larsen PR, Seely EW, Brent GA (1990) Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 323:91-6
130. Mandel SJ, Shankar LK, Benard F, Yamamoto A, Alavi A (2001) Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 26:6-9
131. Mantey SA, Weber HC, Sainz E, Akeson M, Ryan RR, Pradhan TK, Searles RP, Spindel ER, Battey JF, Coy DH, Jensen RT (1997) Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors. J Biol Chem 272:26062-71
132. Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B (2001) Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131) I-MIBG. J Nucl Med 42:1713-21
133. Matthay KK, De Santes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D (1998) Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 16:229-36
134. Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, Hui TE, Martin PJ, Mitchell D, Press OW, et al. (1995) Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 85:1122-31
135. Maxon HR, 3rd, Englaro EE, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD (1992) Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33:1132-6
136. Mazzaferri EL (1999) An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421-7
137. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW, Jr., Lee M,
138. Meller S (1997) Targeted radiotherapy for neuroblastoma. Arch Dis Child 77:389-91
139. Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin C Y, Macey DJ, Austin JM, Jr., Kilgore LC, Grizzle WE, Schlom J, Lo Buglio AF (2001) Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 16:305-15
140. Miano M, Garaventa A, Pizzitola MR, Piccolo MS, Dallorso S, Villavecchia GP, Bertolazzi C, Cabria M, De Bernardi B (2001) Megatherapy combining I (131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant 27:571-4
141. Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212) Pblabeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 20:557-68
142. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22:2522-31
143. Miyazaki M, Lamharzi N, Schally AV, Halmos G, Szepeshazi K, Groot K, Cai RZ (1998) Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Eur J Cancer 34:710-7
144. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K (2000) Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989-95
145. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131) I-meta-iodobenzylguanidine [(131) I-mIBG]. Clin Endocrinol (Oxf) 55:47-60
146. Nelson J, Donnelly M, Walker B, Gray J, Shaw C, Murphy RF (1991) Bombesin stimulates proliferation of human breast cancer cells in culture. Br J Cancer 63:933-6
147. Nock BA, Nikolopoulou A, Galanis A, Cordopatis P, Waser B, Reubi JC, Maina T (2005) Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem 48:100-10
148. O'Donoghue JA, Bardies M, Wheldon TE (1995) Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 36:1902-9
149. Oberg K (1998) Advances in chemotherapy and biotherapy of endocrine tumors. Curr Opin Oncol 10:58-65
150. Oberg K (2001) Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 47 Suppl 2:40-53
151. Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B (2007) Targeted therapy in nuclear medicine-current status and future prospects. Ann Oncol 18:1782-92
152. Oyen WJ (2004) Consolidation therapy with intraperitoneal R1549(Yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer: a phase III trial (abstract) Cancer Biother Radiopharm 19 (4):508
153. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
154. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A (2002) Ablation of thyroid residues with 30 mCi (131) I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-8
155. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A (2003) Recombinant human thyrotropin- stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-73
156. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-32
157. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U (2006) Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616-24
158. Panigone S, Nunn AD (2006) Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging 50:310-21
159. Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20:157-98
160. Postema EJ, Frielink C, Oyen WJ, Raemaekers JM, Goldenberg DM, Corstens FH, Boerman OC (2003) Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother Radiopharm 18:525-33
161. Press OW, Eary JF, Gooley T, Gopal AK, Liu S, Rajendran JG, Maloney DG, Petersdorf S, Bush SA, Durack LD, Martin PJ, Fisher DR, Wood B, Borrow JW, Porter B, Smith JP, Matthews DC, Appelbaum FR, Bernstein ID (2000) A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-42
162. Preston SR, Woodhouse LF, Jones-Blackett S, Miller G V, Primrose JN (1995) High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br J Cancer 71:1087-9
163. Raoul JL, Messner M, Boucher E, Bretagne JF, Campion JP, Boudjema K (2003) Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol. Br J Surg 90:1379-83
164. Raoul JL, Guyader D, Bretagne JF, Heautot JF, Duvauferrier R, Bourguet P, Bekhechi D, Deugnier YM, Gosselin M (1997) Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156-61
165. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD (2006) Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24:115-22
166. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
167. Reubi JC, Waser B (1996) Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer 67:644-7
168. Reubi JC, Schaer JC, Waser B (1997) Cholecystokinin (CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 57:1377-86
169. Reubi JC, Macke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46 Suppl 1:67S-75S
170. Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28:836-46
171. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-82
172. Richman CM, Denardo SJ, O'Donnell RT, Yuan A, Shen S, Goldstein DS, Tuscano JM, Wun T, Chew HK, Lara PN, Kukis DL, Natarajan A, Meares CF, Lamborn KR, De Nardo GL (2005) High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 11:5920-7
173. Risse JH, Grunwald F, Kersjes W, Strunk H, Caselmann WH, Palmedo H, Bender H, Biersack HJ (2000) Intraarterial HCC therapy with I-131-Lipiodol. Cancer Biother Radiopharm 15:65-70
174. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, Casi M, Sarti G, Guiducci G, Giorgetti G, Gentile R, Santimaria M, Jermann E, Maeke HR (1999) Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res 5:3275s-80s
175. Robbins RJ, Schlumberger MJ (2005) The evolving role of (131) I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46 Suppl 1:28S-37S
176. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA (2003) Highdose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98:239-48
177. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638-44
178. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS, Jr., Tyler DS, Olson JA, Jr. (2003) Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134:956-62; discussion 962-3
179. Scemama JL, Zahidi A, Fourmy D, Fagot-Revurat P, Vaysse N, Pradayrol L, Ribet A (1986) Interaction of [125I]-Tyr4-bombesin with specific receptors on normal human pancreatic membranes. Regul Pept 13:125-32
180. Schilder R, Molina A, Bartlett N, Witzig T, Gordon L, Murray J, Spies S, Wang H, Wiseman G, White C (2004) Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm 19:478-81
181. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C (1996) Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606-12
182. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M (2001) Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42:71-6
183. Schmutzler C (2001) Regulation of the sodium/iodide symporter by retinoids-a review. Exp Clin Endocrinol Diabetes 109:41-4
184. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW (2006) A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91:878-84
185. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 30:1378-82
186. 99mTc-leu13-BN1). Cancer Biother Radiopharm 19:245-52
187. Scott AM, Cebon J (1997) Clinical promise of tumour immunology. Lancet 349 Suppl 2:SII19-22
188. Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, Hannah A, Chong G, U P, Papenfuss A, Rigopoulos A, Sturrock S, Murphy R, Wirth V, Murone C, Smyth FE, Knight S, Welt S, Ritter G, Richards E, Nice EC, Burgess AW, Old LJ (2005) A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 11:4810-7
189. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N (2007) 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221-6
190. Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM (2005) A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46:620-33
191. Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM (2003) Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000-18
192. Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD (2003) Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 44:67-76
193. Silberstein EB (2007) Comparison of outcomes after (123) I versus (131) I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 48:1043-6
194. Singh Jaggi J, Henke E, Seshan S V, Kappel BJ, Chattopadhyay D, May C, McDevitt MR, Nolan D, Mittal V, Benezra R, Scheinberg DA (2007) Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE 2:e267
195. Smith CJ, Volkert WA, Hoffman TJ (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32:733-40
196. Smith-Jones PM (2004) Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 48:297-304
197. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH (2003) Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med 44:610-7
198. Solcia E, Buffa R, Gini A, Capella C, Rindi G, Polak JM (1988) Bombesin-related peptides in the diffuse neuroendocrine system. Ann N Y Acad Sci 547:83-94
199. Steffens MG, Kranenborg MH, Boerman OC, Zegwaart-Hagemeier NE, Debruyne FM, Corstens FH, Oosterwijk E (1998) Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 13:133-9
200. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM (2007) Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 17:1277-88
201. Sunday ME (1988) Tissue-specific expression of the mammalian bombesin gene. Ann N Y Acad Sci 547:95-113
202. Sunday ME, Kaplan LM, Motoyama E, Chin WW, Spindel ER (1988) Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab Invest 59:5-24
203. Teunissen JJ, Kwekkeboom DJ, Kooij PP, Bakker WH, Krenning EP (2005) Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. J Nucl Med 46 Suppl 1:107S-14S
204. Troncone L, Rufini V (1997) 131I-MIBG therapy of neural crest tumours (review). Anticancer Res 17:1823-31
205. Tschmelitsch J, Barendswaard E, Williams C, Jr., Yao TJ, Cohen AM, Old LJ, Welt S (1997) Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 57:2181-6
206. Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147-56
207. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP (2005) Long-term follow-up of renal function after peptide receptor radiation therapy with (90) Y-DOTA (0), Tyr (3)-octreotide and (177) Lu-DOTA (0), Tyr (3)-octreotate. J Nucl Med 46 Suppl 1:83S-91S
208. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, De Jong FH, Christiansen A, Kam BL, De Herder WW, Stridsberg M, Lindemans J, Ensing G, Krenning EP (2002) Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 32:110-22
209. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA (2000) Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 27:1694-9
210. Van den Eynde B, Scott AM (1998) Tumor Antigens. Encyclopedia of Immunology. London: Academic press, pp. 2424-31
211. van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, Laissue J, Waser B, Lamberts SW, Visser TJ, Krenning EP (1996) Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 23:1508-13
212. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78-85
213. Van Hazel GA, Price D, Bower G, Sharma RA, Blanshard K, Steward WP (2005) Selective internal radioation therapy (SIRT) for lier metastases with concomitant systemic oxaliplatin, 5-fluorouracil and folinic acid: a phase I/II dose escalation study. J Clin Oncol 23: (Abstract 3657)
214. Van Nostrand D, Wartofsky L (2007) Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 36:807-22, vii-viii
215. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P (2002) In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 32:148-55
216. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116-21
217. von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343-69
218. Vuillez JP, Kraeber-Bodere F, Moro D, Bardies M, Douillard J Y, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF (1999) Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/antidiethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res 5:3259s-67s
219. Wahl RL (2003) The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Semin Oncol 30:31-8
220. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J (2001) The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 12:941-5
221. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, Haldemann A, Mueller-Brand J (2002) Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC. J Nucl Med 43:610-6
222. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, Top LE, Bamford R, Zaknoen E, Roessler E, Kasten-Sportes C, England R, Litou H, Johnson JA, Jackson-White T, Manns A, Hanchard B, Junghans RP, Nelson DL (1995) Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86:4063-75
223. Wiseman GA, White CA, Sparks RB, Erwin WD, Podoloff DA, Lamonica D, Bartlett NL, Parker JA, Dunn WL, Spies SM, Belanger R, Witzig TE, Leigh BR (2001) Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39:181-94
224. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-9
225. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-Lopez AJ (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20 (+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793-803
226. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-63
227. Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA (2003) A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res 9:5842-52
228. Yano T, Pinski J, Groot K, Schally AV (1992) Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52:4545-7
229. Zalutsky MR, Pozzi OR (2004) Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging 48:289-96
230. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC, Maecke HR (2004) Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 64:6707-15